Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: Results from a large multicentre cohort study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1539-1546

  Bai, Anthony D ^a   Showler, Adrienne ^b   Burry, Lisa ^c,d   Steinberg, Marilyn ^c   Ricciuto, Daniel R ^b,e   Fernandes, Tania ^f   Chiu, Anna ^f   Raybardhan, Sumit ^g   Science, Michelle ^h   Fernando, Eshan ^a   Tomlinson, George ^b   Bell, Chaim M ^b,c,i   Morris, Andrew M ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e LAKERIDGE HEALTH CORPORATION   (Canada)

^f CREDIT VALLEY HOSPITAL   (Canada)

^g NORTH YORK GENERAL HOSPITAL   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Bloodstream infections; S. aureus; Staphylococcus aureus

Indexed keywords

BETA LACTAM; CEFAZOLIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSCESS; ABSCESS DRAINAGE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BONE INFECTION; CATHETER INFECTION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DEVICE REMOVAL; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS ARTHRITIS; INTRAVASCULAR CATHETER; JOINT ASPIRATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS BACTEREMIA; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; RELAPSE; RETROSPECTIVE STUDY; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; BACTEREMIA; CLINICAL TRIAL; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFAZOLIN; CLOXACILLIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84929722753     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku560     Document Type: Article

References (25)

1. Chang FY, MacDonald BB, Peacock JE Jr et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 322-32.
2. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006; 333: 281.
3. Kaech C, Elzi L, Sendi P et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006; 12: 345-52.
4. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008; 198: 336-43.
5. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
6. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
7. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
8. Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 1977; 237: 569-70.
9. Fernandez-Guerrero ML, de Gorgolas M. Cefazolin therapy for Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 41: 127.
10. Nannini EC, Singh KV, Murray BE. Relapse of type A b-lactamaseproducing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003; 37: 1194-8.
11. Nannini EC, Stryjewski ME, Singh KV et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009; 53: 3437-41.
12. Paul M, Zemer-Wassercug N, Talker O et al. Are all b-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011; 17: 1581-6.
13. Lee S, Choe PG, Song KH et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother 2011; 55: 5122-6.
14. Li J, Echevarria KL, Hughes DW et al. Comparison of cefazolin versus oxacillin for the treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 5117-24.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
16. Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-7.
17. Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116: 1736-54.
18. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
19. van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012; 25: 362-86.
20. McClelland RS, Fowler VG Jr, Sanders LL et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med 1999; 159: 1244-7.
21. Patel UC, McKissic EL, Kasper D et al. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. Int J Clin Pharm 2014; 36: 1282-9.
22. Gruneir A, Dhalla IA, van Walraven C et al. Unplanned readmissions after hospital discharge among patients identified as being at high risk for readmission using a validated predictive algorithm. Open Med 2011; 5: e104-11.
23. Honda H, Krauss MJ, Jones JC et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123: 631-7.
24. Pastagia M, Kleinman LC, Lacerda de la Cruz EG et al. Predicting risk for death from MRSA bacteremia. Emerg Infect Dis 2012; 18: 1072-80.
25. Forsblom E, Ruotsalainen E, Ollgren J et al. Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 56: 527-35.